Cary Street Partners Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-800	Closed	-$36.3K	–	864
2023 Q3	$36.3K	Hold	800	–	–	﹤0.01%	951
2023 Q2	$44.9K	Hold	800	–	–	﹤0.01%	844
2023 Q1	$36.2K	Sell	800 -550	-41%	-$26.7K	﹤0.01%	820
2022 Q4	$54.9K	Buy	+1,350	New	+$71.6K	﹤0.01%	717
2022 Q3	–	Sell	-1,850	Closed	-$112K	–	515
2022 Q2	$112K	Buy	+1,850	New	+$109K	0.01%	496

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Cary Street Partners Investment Advisory's CRSP Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of CRISPR Therapeutics (CRSP) in Q4 2023, closing a stake of 800 shares — an estimated $36.3K sold.

Cary Street Partners Investment Advisory first reported a position in CRSP in Q2 2022 and held it in 5 quarters. The position peaked at $112K in Q2 2022. 470 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Cary Street Partners Investment Advisory reported no remaining CRISPR Therapeutics position as of Q4 2023 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 800 CRISPR Therapeutics shares in Q4 2023, an estimated $36.3K.
Cary Street Partners Investment Advisory first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 5 quarters.
Cary Street Partners Investment Advisory's CRISPR Therapeutics position peaked at $112K in Q2 2022.
470 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.